Novartis Gears Up for a Pipeline Surge—How Remibrutinib, Pluvicto, & B-Cell Therapies Could Transform Pharma Leadership!

Novartis AG reported a strong financial performance for the second quarter of 2025, marked by double-digit sales growth, core margin expansion, and a subsequent upgrade to its full-year guidance regarding core operating income. The company delivered robust sales growth of 11% in constant currency, while core operating income surged by 21% in constant currency. This financial momentum is largely attributed to significant growth in its priority brands. The flagship products, including Kisqali, Kesimpta, and Pluvicto, all exhibited notable sales increases, underscoring their critical role in driving Novartis’ portfolio expansion.